Shares of Johnson & Johnson (JNJ) Rally 0.12%

On a relative basis, the stock has outperformed the S&P 500 by 2.05% in the past 4 weeks, but has underperformed the S&P 500 in the past 1 week. The stock has continued its bullish performance both in the near-term and the medium-term, as the stock is up 0.12% in the last 1 week, and is up 6.51% in the past 4 weeks. Buying continues as the stock moves higher, suggesting a strong appetite for the stock. The stock has recorded a 20-day Moving Average of 2.79% and the 50-Day Moving Average is 5.85%.

Johnson & Johnson (NYSE:JNJ): The stock opened at $123.77 on Friday but the bulls could not build on the opening and the stock topped out at $124.30 for the day. The stock traded down to $122.71 during the day, due to lack of any buying support eventually closed down at $123.00 with a loss of -0.15% for the day. The stock had closed at $123.18 on the previous day. The total traded volume was 7,192,765 shares.


The company Insiders own 0.11% of Johnson & Johnson shares according to the proxy statements. In the past twelve weeks, the net percent change held by company insiders has changed by -18.24% . Institutional Investors own 68.05% of Johnson & Johnson shares. During last six month period, the net percent change held by insiders has seen a change of -18.24%. In a related news, The officer (Exec VP, WW Chair, Med Devices), of Johnson & Johnson, Pruden Gary J had unloaded 9,735 shares at $116.03 per share in a transaction on June 7, 2016. The total value of transaction was $1,129,552. The Insider information was revealed by the Securities and Exchange Commission in a Form 4 filing.

Johnson & Johnson is a holding company. The Company is engaged in the research and development, manufacture and sale of a range of products in the health care field. The Company has more than 265 operating companies conducting business around the world. The Companys primary focus is products related to human health and well-being. The Company is organized into three business segments: Consumer, Pharmaceutical and Medical Devices. The Companys subsidiaries operate 134 manufacturing facilities occupying approximately 21.5 million square feet of floor space. The Companys research facilities are located in the United States, Belgium, Brazil, Canada, China, France, Germany, India, Israel, Japan, the Netherlands, Singapore, Switzerland and the United Kingdom.

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *

Get Pre-Market Alerts!

Get Pre-Market Analysts' Upgrades, Downgrades, Earnings & Initiations with our FREE daily email newsletter.